Obesity can be accompanied not only with eating disorders, but also with psychological disorders. Many patients may require concomitant use of a drug for weight loss, such as Metermine together with sedative drugs. How safe is Metermine interaction with antidepressants?

Monoamine oxidase inhibitors (MAO) are often used to treat depressive disorders. Antidepressants of a group of MAO, such as Phenelzine, Moclobemide and Selegiline are well known.

Principle of action of MAO is to inhibit enzyme of monoamine oxidase.

The enzyme has a devastating impact on the most important neurotransmitters, including norepinephrine and dopamine.

Blockage of production of monoamine oxidase contributes to increased concentration of neurotransmitters in the brain and to provision of an antidepressant effect.

Just as MAO, Metermine affects noradrenergic and dopaminergic systems.

  • Accumulation of noradrenaline and dopamine in the brain hypothalamus eliminates feeling of excessive hunger and reduces the amount of food consumed.

As this anorectic and MAO have similar effect on the body, Metermine interaction with antidepressants is potentially dangerous to health. Synergistic effect of this anorectic and MAO increases the risk of side effects. The most common adverse reactions of Metermine interaction with MAO antidepressants are Tyramine syndrome and Serotonin syndrome.

Intake of MAO antidepressants increases pressor effect of Metermine in the body.

During Tyramine syndrome, a sharp rise in blood pressure (hypertensive crisis) occurs. In Tyramine syndrome, the person experiences severe headaches, excessive sweating, heart pain and other symptoms.

Serotonin syndrome – is another unfavorable reaction of the body, which can occur during Metermine interaction with antidepressants.

Serotonin syndrome is characterized by hyperstimulation of serotonin receptors because of which side effects involving gastrointestinal tract and the nervous system occur.

To reduce the risk of side effects, this anorectic and MAO drugs should be taken separately. The patient can start using Metermine at least two weeks after application of any drug of MAO group.

There is no information about whether Metermine can interact or not with antidepressants of other pharmaceutical groups – tricyclics, selective serotonin reuptake inhibitors (SSRIs), or with others in indication to the use.

Nevertheless, Metermine is a centrally acting drug, and it is not recommended for patients prone to depressive disorders. Avoid Metermine interaction with antidepressants of any pharmaceutical groups.